Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the efficacy and promise of BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory (R/R) multiple myeloma. Ide-cel was approved in March 2021 for patients with R/R multiple myeloma based on the results of the Phase II KarMMA study (NCT03361748) which reported a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months. The field of CAR-T therapies for multiple myeloma is rapidly evolving, notably with cilta-cel, which showed remarkable results in the Phase Ib/II CARTITUDE-1 trial (NCT03548207), with an overall response rate (ORR) of almost 98% and a 2-year PFS of 71%. In addition, the incidence of severe cytokine release syndrome (CRS) and neurotoxicity was low. These trials highlight the potency of BCMA-directed CAR-T therapies for R/R multiple myeloma and several clinical trials are now evaluating these approaches in earlier lines of treatment. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.